US senators push drugmakers for details on low-cost insulin programs

Two U.S. senators are demanding that the nation's three largest insulin makers, Novo Nordisk , Eli Lilly, and Sanofi, provide details by Sept. 15 of their programs to help Americans get their insulin for $35 a month or less.